Check 35,000+ stocks against 26 valuation models and 37 quality factors

Eyepoint Pharmaceuticals Inc (EYPT) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Eyepoint Pharmaceuticals Inc $2.75, price $3.72, upside -26.2%, quality 22 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · US · ISIN US30233G2093

Thin data Sep 23, 2026

Eyepoint Pharmaceuticals Inc

EYPT · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $2.75 · Overvalued (−26%)

!Quality 22/100

!Weak Growth (revenue 5y −1.8 %/yr)

!Low debt · negative free cash flow

!Trails peers (2/6)

!Narrow moat 11/100

✓Insider activity 66/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear $1.81 to bull $3.43 Growth analysisrevenue history, year by year Quality 22/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Eyepoint Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $2.28 – $29.71 · fair‑value band $1.81 – $3.43 · the $3.72 price screens above the $2.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Eyepoint Pharmaceuticals in your weekly email

Every Wednesday you see whether Eyepoint Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Stock analysis

Eyepoint Pharmaceuticals Inc (EYPT) currently trades at $3.72, while our model-based Fair Value estimate is $2.75, implying the stock looks roughly 35.5% overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $1.81 (bear) to $3.43 (bull), the price of $3.72 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Eyepoint Pharmaceuticals Inc reported revenue of $31.4M in FY2025 versus $36.9M in FY2021, a compound −4.0%/yr. Reported net income was −$232M in FY2025.

Key figures

Market cap $1.1B · EPS (TTM) $−3.51 · Return on equity −103% · Return on assets (EBIT) −39.8% · Operating margin −451% · Revenue growth (YoY) +162% · Free cash flow −$243M · Net cash $81.0M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 39 out of 100 (low confidence).

What moves the price

The share trades about 80% below its 52-week high and 8% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −26%, EYPT screens richer than that median.

Fair Value models

Bear $1.81 Fair Value $2.75 Bull $3.43

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

NCAV (Graham) $1.83 $2.45 $3.65 54

All 1 models by family

Asset-Based

NCAV (Graham) $1.83 $2.45 $3.65 54

Open the full fair value analysis →

Notify me when EYPT reaches fair value

Put EYPT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 22/100

Of which business quality 28 · Market factors (momentum, volatility) 1

Profitability 3

Margins and returns on capital today

Quality Growth 22

Are margins and returns improving?

Cashflow 12

Earnings quality: real cash, not paper profit

Fin. Strength 97

Balance sheet, leverage, solvency risk

Investment 18

Disciplined investing over empire-building

Low Volatility 2

Calm price path (market factor)

Momentum 0

Price trend over the last 3–12 months (market factor)

52W Momentum 1

Distance to the 52-week high (market factor)

Net Issuance 0

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100

Revenue is shrinking: the last year, the last three and the last five years are all negative.

Revenue growth 1 year

−27.5%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−8.8%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.8%

Start year 2020 (pandemic). Over 10 years: +1.7% a year

Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+18.7%

’12

’13

’14

’15

’17

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−108.3% (2020) → −776.0% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

EYPT screens 35% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Eyepoint Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 2/6 measures

Overall it trails its industry peers.

Valuation

Quality Score 28 · Bottom 25%

Fair Value upside −33% · Above median

Profitability

Return on assets −54% · Bottom 25%

Growth and dividend

Revenue growth 162% · Top 25%

Balance sheet

Debt / equity 0.10× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.72× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 0

FUTURE (revenue growth)100 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)95 · sector 97

DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	$514.99	$566.49	+10%
Regeneron Pharmaceuticals, Inc REGN	$803.90	$1,252	+56%
argenx SE ARGX	$963.79	$918.60	−5%
Samsung Biologics Co 207940	1,366,000 KRW	1,502,600 KRW	+10%
CSL Limited CSL	A$179.24	A$197.16	+10%
Alnylam Pharmaceuticals, Inc ALNY	$251.65	$218.36	−13%
Royalty Pharma plc RPRX	$58.52	$24.22	−59%
Celltrion, Inc 068270	177,400 KRW	74,519 KRW	−58%
BeOne Medicines AG ONC	$368.08	$280.94	−24%
BioNTech SE BNTX	$100.87	$63.62	−37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Eyepoint Pharmaceuticals Inc · Fair Value
$2.75 −35%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/EYPT" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Eyepoint Pharmaceuticals Inc · Fair Value</span><br><b style="font-size:20px">$2.75</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−35%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Eyepoint Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/EYPT

Frequently asked questions

Is Eyepoint Pharmaceuticals Inc (EYPT) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $2.75 versus a price of $3.72, about −26% upside (overvalued).

What is the fair value of EYPT?

Our model-based fair value for Eyepoint Pharmaceuticals Inc is $2.75 (as of Sep 23, 2026), built from audited fundamentals. The current price: $3.72.

What is the quality score of EYPT?

Eyepoint Pharmaceuticals Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Eyepoint Pharmaceuticals Inc (EYPT)?

Our model-based price target is the fair value of $2.75 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $1.81, optimistic scenario $3.43. It is a calculation from audited fundamentals, not an analyst target.

What is the Eyepoint Pharmaceuticals Inc stock forecast for 2026?

Our models put fair value at $2.75, about −26% upside versus a price of $3.72 (overvalued). Cautious scenario $1.81, optimistic scenario $3.43. The calculation is refreshed regularly with new filings.

What is the intrinsic value of Eyepoint Pharmaceuticals Inc (EYPT)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Eyepoint Pharmaceuticals Inc it is $2.75 per share (as of Sep 23, 2026), against a price of $3.72. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).

Is Eyepoint Pharmaceuticals Inc stock overvalued or undervalued in 2026?

As of Sep 23, 2026, EYPT trades above its calculated fair value: price $3.72, fair value $2.75, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of EYPT?

No. The price is what the market pays today ($3.72); the fair value is what the company's own numbers justify ($2.75). For Eyepoint Pharmaceuticals Inc the two are $0.9740 per share apart. That gap is exactly why we show both numbers side by side.

How much is Eyepoint Pharmaceuticals Inc worth?

The market values Eyepoint Pharmaceuticals Inc at about $1.1B (market capitalisation, as of Sep 23, 2026). Per share that is $3.72; our models calculate a fair value of $2.75 per share.

What do the bullish and bearish scenarios say about EYPT?

Our models span a range for Eyepoint Pharmaceuticals Inc: cautious scenario $1.81, base $2.75, optimistic $3.43 per share (as of Sep 23, 2026, price $3.72). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Eyepoint Pharmaceuticals Inc (EYPT)?

Balance-sheet figures for Eyepoint Pharmaceuticals Inc (as of Sep 23, 2026): return on equity −102.7%, debt of 0.10 per unit of equity. They feed the Quality Score of 22/100, which measures business quality independently of the share price.

How far is EYPT from its 52-week high?

Eyepoint Pharmaceuticals Inc trades at $3.72, about 80% below its 52-week high of $18.85 and 8% above the low of $3.45 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $2.75 is for.

Which stocks are comparable to Eyepoint Pharmaceuticals Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Eyepoint Pharmaceuticals Inc stock attractive at the current price?

The data as of Sep 23, 2026: price $3.72, calculated fair value $2.75 (−26%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of EYPT calculated?

We run Eyepoint Pharmaceuticals Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $2.75, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Eyepoint Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Eyepoint Pharmaceuticals Inc (EYPT)?

The closing price on Sep 23, 2026 was $3.72. Our model-based fair value is $2.75, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Eyepoint Pharmaceuticals Inc right now?

The price sits above even our optimistic bull case ($3.43). The favourable scenario is already priced in. Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($1.81 to $3.43) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Eyepoint Pharmaceuticals Inc

How large is the market capitalisation of Eyepoint Pharmaceuticals Inc (EYPT)?

The market capitalisation of Eyepoint Pharmaceuticals Inc is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Eyepoint Pharmaceuticals Inc (EYPT)?

Earnings per share at Eyepoint Pharmaceuticals Inc are $−3.51. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Eyepoint Pharmaceuticals Inc (EYPT)?

The return on equity (ROE) of Eyepoint Pharmaceuticals Inc is −103% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Eyepoint Pharmaceuticals Inc (EYPT)?

On an EBIT basis the return on assets of Eyepoint Pharmaceuticals Inc is −39.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Eyepoint Pharmaceuticals Inc (EYPT)?

The operating margin of Eyepoint Pharmaceuticals Inc is −451% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Eyepoint Pharmaceuticals Inc (EYPT)?

Revenue at Eyepoint Pharmaceuticals Inc is growing +162% versus a year earlier (3y avg −8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How much free cash flow does Eyepoint Pharmaceuticals Inc (EYPT) generate?

The free cash flow of Eyepoint Pharmaceuticals Inc is −$243M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Eyepoint Pharmaceuticals Inc (EYPT) hold?

Eyepoint Pharmaceuticals Inc holds more cash than debt, $81.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Eyepoint Pharmaceuticals Inc in the live analysis

One click puts Eyepoint Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.